Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Treasury Shares (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Treasury Shares for 4 consecutive years, with $728283.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 409.28% to $728283.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $728283.0 through Dec 2025, up 409.28% year-over-year, with the annual reading at $728283.0 for FY2025, 409.28% up from the prior year.
  • Treasury Shares hit $728283.0 in Q4 2025 for NewAmsterdam Pharma, roughly flat from $724908.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $728283.0 in Q4 2025 to a low of $143002.0 in Q4 2024.
  • Historically, Treasury Shares has averaged $603478.8 across 4 years, with a median of $614942.1 in 2022.
  • Biggest five-year swings in Treasury Shares: plummeted 76.51% in 2024 and later surged 409.28% in 2025.
  • Year by year, Treasury Shares stood at $621105.2 in 2022, then dropped by 1.98% to $608779.0 in 2023, then tumbled by 76.51% to $143002.0 in 2024, then soared by 409.28% to $728283.0 in 2025.
  • Business Quant data shows Treasury Shares for NAMS at $728283.0 in Q4 2025, $724908.0 in Q3 2025, and $718584.0 in Q2 2025.